Litfulo (ritlecitinib) — prior authorization for alopecia areata
Customize your policy alerts
Sign up for all medical mutual - ohio policy alerts
Know when medical mutual - ohio releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization guidance for pharmacy benefit coverage of Litfulo (ritlecitinib) for treatment of alopecia areata in patients aged 12 years and older; describes approval criteria, durations, and conditions not recommended for approval.
No material clinical or coverage changes in this revision.
Coverage Criteria for Litfulo (ritlecitinib)
Initial Therapy and Continuation Therapy
Approve when ALL of the following criteria are met for Initial Therapy (A) or Continuation (B):
Initial Therapy (A)
- Age: Patient is >= 12 years of age>= 12 years
- Episode duration: Patient has a current episode of alopecia areata lasting >= 6 months>= 6 months
- Extent: Patient has >= 50% scalp hair loss>= 50%
- Prior therapies: Patient has tried at least one of: (a) conventional systemic therapy OR (b) high- or super-high potency topical corticosteroid
Examples of conventional systemic therapies include corticosteroids, methotrexate, and cyclosporine; exception if patient has already tried Leqselvi or Olumiant
- Exclusion of other causes: Patient does not have hair loss due to androgenetic alopecia, chemotherapy-induced hair loss, or other causes of hair loss other than alopecia areata
- Prescriber: Medication is prescribed by or in consultation with a dermatologist (specialist)
Currently Receiving Litfulo (B)
- Age: Patient is >= 12 years of age>= 12 years
- Established therapy: Patient has been established on Litfulo for at least 6 months>= 6 months on therapy
Patients with <6 months or restarting are reviewed under Initial Therapy
- Clinical response: Patient experienced a beneficial clinical response defined as improvement from baseline in extent and density of scalp hair lossimprovement from baseline
- Ongoing need: Prescriber indicates patient continues to require systemic therapy for alopecia areata
International consensus: discontinue systemic treatment once complete regrowth maintained for 6 months or when regrowth manageable topically
Use caution and do not approve Litfulo when it would be used concurrently with other systemic biologic therapies or targeted synthetic oral small-molecule drugs for inflammatory conditions. Do not administer Litfulo in combination with another biologic or a targeted synthetic oral small molecule drug because combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy.
The policy excludes hair loss from causes other than alopecia areata. Coverage is not appropriate for hair loss due to androgenetic alopecia (male or female pattern hair loss), chemotherapy‑induced hair loss, trichotillomania, telogen effluvium, or systemic lupus erythematosus. These etiologies do not meet the Recommended Authorization Criteria.
Coverage is not recommended for concurrent administration of Litfulo with other immunomodulatory or immunosuppressive agents. Specifically, do not combine Litfulo with another JAK inhibitor (including topical JAK inhibitors), with other biologics, or with biologic immunomodulators. Co‑administration with other potent immunosuppressants (for example, cyclosporine or azathioprine) is also discouraged because of added immunosuppression and absence of data demonstrating safety or additive benefit.
Litfulo should only be considered for the indications and patient circumstances explicitly listed in the Recommended Authorization Criteria. Coverage is not recommended for uses, combination regimens, or clinical situations that are not specified in those criteria; the policy will be updated as new published data become available.
Clinical Thresholds and Coding-related Criteria
Initial Therapy — Authorization Rules
Initial Therapy
Approve when ALL of the following criteria are met for Initial Therapy (A) or Continuation (B):
Initial Therapy (A)
- Age: Patient is >= 12 years of age>= 12 years
- Episode duration: Patient has a current episode of alopecia areata lasting >= 6 months>= 6 months
- Extent: Patient has >= 50% scalp hair loss>= 50%
- Prior therapies: Patient has tried at least one of: (a) conventional systemic therapy OR (b) high- or super-high potency topical corticosteroid
Examples of conventional systemic therapies include corticosteroids, methotrexate, and cyclosporine; exception if patient has already tried Leqselvi or Olumiant
- Exclusion of other causes: Patient does not have hair loss due to androgenetic alopecia, chemotherapy-induced hair loss, trichotillomania, telogen effluvium, systemic lupus erythematosus, or other non–alopecia areata causes
Concurrent use with other biologics, topical JAK inhibitors, biologic immunomodulators, or other potent immunosuppressants is not recommended
- Prescriber: Medication is prescribed by or in consultation with a dermatologist (specialist)
Prior authorization recommended; initial prescriptions must be by or in consultation with a specialist
Currently Receiving Litfulo (B)
- Age: Patient is >= 12 years of age>= 12 years
- Established therapy: Patient has been established on Litfulo for at least 6 months>= 6 months on therapy
Patients with <6 months or restarting are reviewed under Initial Therapy
- Clinical response: Patient experienced a beneficial clinical response defined as improvement from baseline in extent and density of scalp hair lossimprovement from baseline
- Ongoing need: Prescriber indicates patient continues to require systemic therapy for alopecia areata
International consensus: discontinue systemic treatment once complete regrowth is maintained for 6 months or when regrowth is manageable with topical therapy
Ensure records demonstrate prior therapy trials, extent/duration of hair loss, specialist involvement, and clinical response as applicable
Document type, dose, and duration of prior therapies in medical record
Fail‑first/conservative therapy required before initial approval
Require evidence of a prior trial of at least one conservative therapy before initial approval. The patient must have tried either (a) a conventional systemic therapy (examples: corticosteroids, methotrexate, cyclosporine) or (b) a high- or super-high potency topical corticosteroid; an exception to this trial requirement is allowed if the patient has already tried Leqselvi (deuruxolitinib) or Olumiant (baricitinib).
- Trial of ≥1 conventional systemic therapy OR a high- or super-high potency topical corticosteroid is required prior to initial approval.
- Examples of conventional systemic therapies: corticosteroids, methotrexate, cyclosporine.
- Exception: no conservative-therapy trial required if patient has already tried Leqselvi (deuruxolitinib) or Olumiant (baricitinib).
Continuation Therapy — Renewal Rules
Continuation Therapy
Criteria for patients currently receiving Litfulo
Patients with <6 months or restarting are reviewed under initial therapy
Prescriber and Documentation Requirements
Prior authorization and specialist prescriber required
Prior authorization is recommended for pharmacy benefit coverage of Litfulo; initial prescriptions must be by or in consultation with a physician who specializes in the condition being treated.
Fail‑first / conservative therapy required before initial approval
Initial approval requires trial of at least one conventional systemic therapy OR a high- or super-high‑potency topical corticosteroid; exception allowed if the patient has already tried Leqselvi (deuruxolitinib) or Olumiant (baricitinib).
- Conventional systemic therapy examples include corticosteroids, methotrexate, and cyclosporine.
- If patient has tried Leqselvi or Olumiant, the conventional‑therapy requirement can be waived.
Provide records, test results, and provider credentials on request
The Company may request additional documentation to support medical necessity; requested materials may include patient records, test results, and/or credentials of the provider ordering or performing the service.
Denial risk if documentation or medical necessity not met
The Company may deny reimbursement when the drug or services are not medically necessary, are investigational or experimental, are not within the member's benefit scope, or when a pattern of billing or other practice is inappropriate or excessive.
Background on Litfulo (ritlecitinib)
Litfulo (ritlecitinib) is a kinase inhibitor in the JAK/TEC pathway indicated for treatment of severe alopecia areata in patients aged ≥ 12 years. Initial prescribing and monitoring should involve specialist expertise (for example, a dermatologist) because evaluation, diagnosis, monitoring for adverse events, and assessment of long‑term efficacy require dermatologic oversight. The policy cautions against combination use with other JAK inhibitors, biologics, biologic immunomodulators, or potent immunosuppressants due to safety concerns and limited evidence for additive efficacy.
Definitions and Examples
Prescribing Site of Care Recommendation
Specialist involvement for initial prescribing
Initial prescribing should be by or in consultation with a physician who specializes in the condition being treated (e.g., dermatologist).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.